Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Post-Mkt 08-14 17:36:01 EDT

1.02

-0.15

-13.25%

盘后1.05

+0.03+3.27%

16:41 EDT

High1.12	Low0.9942	Vol427.90K
Open1.12	D1 Closing1.17	Amplitude10.75%
Mkt Cap16.22M	Tradable Cap9.88M	Total Shares15.98M
T/O444.17K	T/O Rate4.40%	Tradable Shares9.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":1.015,"timestamp":1786737600000,"preClose":1.17,"halted":0,"volume":427899,"hourTrading":{"tag":"盘后","latestPrice":1.0482,"preClose":1.015,"latestTime":"16:41 EDT","volume":633,"amount":641.4781488,"timestamp":1786740097767,"change":0.0332,"changeRate":0.032709,"amplitude":0.078227},"delay":0,"changeRate":-0.1324786324786325,"floatShares":9731600,"shares":15979411,"eps":-5.7,"marketStatus":"Post-Mkt","change":-0.155,"latestTime":"08-14 17:36:01 EDT","open":1.12,"high":1.12,"low":0.9942,"amount":444169.0464669,"amplitude":0.107521,"askPrice":1.09,"askSize":100,"bidPrice":0.9747,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-5.7,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786752000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.17,"preHourTrading":{"tag":"盘前","latestPrice":1.1116,"preClose":1.17,"latestTime":"09:26 EDT","volume":21159,"amount":23518.863269999998,"timestamp":1786713978016,"change":-0.0584,"changeRate":-0.049915,"amplitude":0.110171},"postHourTrading":{"tag":"盘后","latestPrice":1.0482,"preClose":1.015,"latestTime":"16:41 EDT","volume":633,"amount":641.4781488,"timestamp":1786740097767,"change":0.0332,"changeRate":0.032709,"amplitude":0.078227},"volumeRatio":0.716115,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2659819807","title":"Tempest Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659819807","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659819807?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:44","pubTimestamp":1786657486,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryTempest Therapeutics IncTPST.OQreported a quarterly adjusted loss of 34 cents per share for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A2BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659833160","title":"Tempest Therapeutics Enters USD 50 Million Equity Purchase Deal with Lincoln Park Capital Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2659833160","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659833160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:39","pubTimestamp":1786653581,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics enters USD 50 million equity purchase deal with Lincoln Park Capital FundTempest Therapeutics set a $50 million equity line with Lincoln Park Capital to sell common stock in unreg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7r9t7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167249","title":"Tempest Therapeutics - Enters $50 Mln Common Stock Purchase Agreement with Lincoln Park - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167249?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:34","pubTimestamp":1786653268,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A1N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659216791","title":"Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659216791","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659216791?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:25","pubTimestamp":1786652700,"startTime":"0","endTime":"0","summary":"-- Unveiled next-generation in vivo CAR-T pipeline, including lead. product candidate TPST-4003, a dual-targeting CD19/BCMA CAR-T that. with its clinically validated dual-target CAR architecture for. -- Executed a strategic partnership with Hebei Senlang Biotechnology. to collaborate on the development of Tempest's certain proprietary. in vivo CAR-T product candidates, including its CD7-targeted. beginning with an investigator-initiated trial in China evaluating. TPST-4003 in approximately 10 patients with myasthenia gravis or. multiple sclerosis. The company expects first patient enrollment. and dosing to occur in the fourth quarter of 2026.-- Reported positive interim results across two ongoing clinical. trials (REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","EMD","CAR","BK4139","BK4022","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657364268","title":"Tempest Therapeutics Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657364268","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657364268?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:57","pubTimestamp":1786114653,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc <TPST.OQ> expected to post a loss of30cents a share - Earnings PreviewTempest Therapeutics IncTPST.OQTPST.Ois expected to  show no change in quarterly revenue when it reports  results on August 10  for the period ending June 30 2026LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of 30 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Tempest Therapeutics Inc is $11.00, about 1,119% above its last closing price of $0.90This summary was machine generated August 7 at 14:57 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927116","title":"Tempest Therapeutics Partners with Senlang Biotech to Advance Tpst-4003 in Vivo CAR-T into First-in-human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927116","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653927116?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:06","pubTimestamp":1784631963,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trialTempest Therapeutics entered a development collaboration with Senlang Biotechnology to ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDLc0TkGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BCDF","TPST","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653715512","title":"Tempest Announces Development Collaboration with Senlang Biotechnology for Tpst-4003, a Cd7-targeted Next-generation in Vivo CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2653715512","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653715512?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA19KSRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653591271","title":"Tempest Therapeutics - Co and Senlang to Develop Tpst-4003 with Trial in China for Mg and MS","url":"https://stock-news.laohu8.com/highlight/detail?id=2653591271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653591271?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA19KSRH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271304","title":"Tempest Therapeutics - First Patient Dosing for Tpst-4003 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271304?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA19KSRH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652425357","title":"How Jakarta Plans to End Open Dumping in Bantargebang","url":"https://stock-news.laohu8.com/highlight/detail?id=2652425357","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652425357?lang=en_us&edition=fundamental","pubTime":"2026-07-18 19:11","pubTimestamp":1784373109,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -The Jakarta Provincial Government is preparing to phase in a controlled landfill system at the Bantargebang Integrated Waste Treatment Plant  starting August 1, 2026, as part of its transition toward eliminating open dumping practices and upgrading waste management.\"Starting August 1, we will begin a gradual transition from open dumping practices to controlled landfill management. The government is responsible for ensuring this change runs smoothly,\" said Dudi Gardesi, Head of the Jakarta Environmental Agency, in an official statement on Saturday.He explained that the transition will be carried out in phases to avoid disrupting waste transportation and disposal services from the capital.","market":"nz","thumbnail":"https://statik.tempo.co/data/2026/07/06/id_1481005/1481005_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/07/06/id_1481005/1481005_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2114325/how-jakarta-plans-to-end-open-dumping-in-bantargebang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2114325/how-jakarta-plans-to-end-open-dumping-in-bantargebang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["SES.SI","BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745208","title":"Tempest Therapeutics Plans First Clinical Study of in Vivo CAR-T Candidate Tpst-4003 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745208","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651745208?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:02","pubTimestamp":1784113376,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics plans first clinical study of in vivo CAR-T candidate TPST-4003 in Q4 2026Tempest Therapeutics unveiled an in vivo CAR-T platform, setting a first clinical study of lead candidate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL27rPh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BCDF","SG9999014013.SGD","TPST","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647792643","title":"Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford","url":"https://stock-news.laohu8.com/highlight/detail?id=2647792643","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647792643?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:03","pubTimestamp":1782734616,"startTime":"0","endTime":"0","summary":"Rani Therapeutics names Nicholas Maestas CFO, replacing Svai SanfordRani Therapeutics appointed Nicholas Maestas as chief financial officer, effective immediately.Maestas previously served as CFO, hea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL3WzsD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4007","BK4139","RANI","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","TPST","BK4588","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4585","BK4112","LU2095319765.USD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646983813","title":"Tempest Therapeutics Registers 2.43 Million Shares for Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2646983813","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646983813?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:47","pubTimestamp":1782506846,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  filed a prospectus Friday to register up to 2.43 million shares of common stock for resale by selling stockholders, representing shares issuable upon exercise of warrants from a May inducement agreement and related placement-agent warrants.The warrants have a $1.73 exercise price and expire May 29, 2028. If exercised for cash, they would generate about $4.23 million in gross proceeds for Tempest, which plans to use the funds for working capital and general corporate purposes. The company will not receive proceeds from the resale.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TPST","BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646367044","title":"Tempest Therapeutics - Selling Stockholders May Offer up to 2.43 Mln Shares of Tempest Therapeutics Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646367044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646367044?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:04","pubTimestamp":1782504240,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42Y15Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646806319","title":"Jakarta Offers Prizes for Waste Sorting on Anniversary Peak Night","url":"https://stock-news.laohu8.com/highlight/detail?id=2646806319","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646806319?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:15","pubTimestamp":1782393318,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-The Jakarta provincial government invites the public attending the peak night of Jakarta's 499th anniversary to participate in a waste sorting movement. The invitation was communicated through the official Instagram account @dkijakarta, where citizens can take part in the #JagaJakarta challenge by sorting their waste during the event at HI Roundabout on Saturday, June 27, 2026.As a form of appreciation, the committee will provide prizes in the form of free tickets to Ancol, Dufan, and Atlantis for participants who complete the challenge.This program is part of a large-scale movement by the Jakarta provincial government to change how citizens manage waste. It is in line with Governor's Instruction Number 5 of 2026, which requires citizens to sort waste at its source. This movement is crucial considering the waste emergency in Jakarta. The Bantargebang Integrated Waste Treatment Site  is already more than 86.4 percent full.","market":"nz","thumbnail":"https://statik.tempo.co/data/2026/06/11/id_1477373/1477373_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/06/11/id_1477373/1477373_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2110406/jakarta-offers-prizes-for-waste-sorting-on-anniversary-peak-night","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2110406/jakarta-offers-prizes-for-waste-sorting-on-anniversary-peak-night","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["SKIS","TPST","RW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645798851","title":"Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2645798851","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645798851?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:56","pubTimestamp":1782248214,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics CEO and President Matthew Angel reported indirect beneficial ownership of 231,482 common shares held by Factor Bioscience.Factor also held Series A warrants for 231,482 shares, exercisable at USD 2.16, subject to stockholder approval.Series B warrants covered another 231,482 shares at USD 2.16, also contingent on stockholder approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL2PSDBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645488744","title":"Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645488744","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645488744?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:03","pubTimestamp":1782209029,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics held a special stockholder meeting on June 18, 2026.Stockholders authorized issuance of up to 925,927 shares tied to Series A warrants.They also authorized issuance of up to 925,927 shares tied to Series B warrants from a March 20, 2026 private placement.A separate authorization cleared issuance of up to 2,344,828 shares tied to common warrants from a May 28, 2026 inducement offer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL9bcGsS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644772709","title":"Tempest Therapeutics director John D. Yee files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644772709","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644772709?lang=en_us&edition=fundamental","pubTime":"2026-06-18 07:20","pubTimestamp":1781738429,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics director John David Yee filed an initial Form 3 disclosure dated June 4, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLrPk67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642584044","title":"Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642584044","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642584044?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:01","pubTimestamp":1780966903,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics director William Drake Richey reported 2,000 shares of common stock in an initial Form 3 filing dated June 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLqQyft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641491167","title":"Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641491167","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641491167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:01","pubTimestamp":1780606914,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":0.2965},{"period":"1month","weight":0.1933},{"period":"3month","weight":-0.3607},{"period":"6month","weight":-0.5042},{"period":"1year","weight":-0.8747},{"period":"ytd","weight":-0.5923}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.113004},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.011916},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.124765},{"month":7,"riseRate":0.214286,"avgChangeRate":-0.03977},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.024169},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}